News

GDNF is a naturally-occurring growth factor capable of protecting and promoting the survival of dopamine producing nerve cells. MedGenesis chairman and CEO Erich Mohr said they hope that

The FDA considers the resubmission a complete, class 2 response and assigned a new Prescription Drug User Fee Act (PDUFA) target date of 27 June 2012, the company

The rhFSH analog is developed through Trophogen’s proprietary superagonist hormone technology platform originally licensed from the National Institutes of Health. The contract manufacturing deal includes the technology transfer

Cubist and Hydra have recently identified and completed preclinical testing on a novel small molecule antagonist of the human TRPA1 channel, CB-625 (CB-189,625), and filed for regulatory approval

The certificate was granted following inspection of the facility in November 2011. Ablynx’s GMP unit will now perform release-testing on Drug Substance and Drug Product batches besides independently

The $3.1m deal is believed to help gain deep insights into the insulin-producing beta cells which are destroyed in type 1 diabetes and produce little insulin in type

As per the alliance, Forma will be responsible for the discovery and development of drugs against a range of tumor metabolism targets and will be entitled to receive

Levotofisopam, the S-entantiomer of the racemic mixture RS-tofisopam, is said to be a well tolerated, effective, nonsedating agent used to treat various disorders related to stress or autonomic

Pharmacy Xpert, whicht belongs to the Clinical Xpert Suite of workflow solutions, is a clinical intelligence dashboard that aids hospital pharmacists in improving outcomes, reducing costs, and managing